Abstract
Purpose
Our aim is to examine the associations between high-sensitivity C-reactive protein (hsCRP) and hemoglobin A1c (HbA1c), common biomarkers of inflammation and insulin resistance, respectively, with breast cancer risk, while adjusting for measures of excess body size.
Methods
We conducted a nested case–control study within the Alberta’s Tomorrow Project cohort (Alberta, Canada) including 197 incident breast cancer cases and 394 matched controls. The sample population included both pre- and postmenopausal women. Serum concentrations of hsCRP and HbA1c were measured from blood samples collected at baseline, along with anthropometric measurements, general health and lifestyle data. Conditional logistic regression was used to evaluate associations between hsCRP, HbA1c, and breast cancer risk adjusted for excess body size (body fat percentage) and other risk factors for breast cancer.
Results
Higher concentrations of hsCRP were associated with elevated breast cancer risk (odds ratio [OR] 1.27; 95% confidence interval [95% CI] 1.03–1.55). The observed associations were unchanged with adjustment for body fat percentage. Higher HbA1c concentrations were not significantly associated with an increased breast cancer risk (OR 1.22; 95% CI 0.17–8.75).
Conclusion
These data suggest that hsCRP may be associated with elevated breast cancer risk, independent of excess body size. However, elevated concentrations of HbA1c did not appear to increase breast cancer risk in apparently healthy women.
Similar content being viewed by others
References
Canadian Cancer Society (2018) Canadian Cancer Statistics: a 2018 special report on cancer incidence by stage. Canadian Cancer Society, Toronto, ON
Canadian Cancer Society (2019) Canadian Cancer Society's Advisory Committee on Cancer Statistics, breast cancer statistics. Canadian Cancer Society, Toronto, ON
World Cancer Research Fund/American Institute for Cancer Research, Diet, Nutrition, physical activity and cancer: a global perspective. Continuous update project expert report 2018. 2018, WCRF/AICR.
Jarde T et al (2011) Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 47(1):33–43
Perks CM, Holly JM (2011) Hormonal mechanisms underlying the relationship between obesity and breast cancer. Endocrinol Metab Clin N Am 40(3):485–507
Roberts DL, Dive C, Renehan AG (2010) Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 61:301–316
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Colotta F et al (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7):1073–1081
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539–545
Wiseman H, Halliwell B (1996) Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313(Pt 1):17–29
Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111(12):1805–1812
Allin KH, Nordestgaard BG (2011) Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 48(4):155–170
Kaur RP et al (2018) Association of elevated levels of C-reactive protein with breast cancer, breast cancer subtypes, and poor outcome. Curr Probl Cancer 43:123–129
Heikkila K et al (2007) Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women's Heart and Health Study. Cancer Epidemiol Biomarkers Prev 16(6):1155–1159
Alokail MS et al (2013) Metabolic syndrome biomarkers and early breast cancer in Saudi women: evidence for the presence of a systemic stress response and/or a pre-existing metabolic syndrome-related neoplasia risk? BMC Cancer 13:54
Dossus L et al (2014) C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study. Cancer Causes Control 25(4):533–539
Gaudet MM et al (2013) Obesity-related markers and breast cancer in CPS-II Nutrition Cohort. Int J Mol Epidemiol Genet 4(3):156–166
Hong T et al (2013) Preoperative serum C-reactive protein levels and early breast cancer by BMI and menopausal status. Cancer Invest 31(4):279–285
Il'yasova D et al (2005) Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 14(10):2413–2418
Ollberding NJ et al (2013) Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res (Phila) 6(3):188–195
Prizment AE et al (2013) Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study. Cancer Causes Control 24(12):2077–2087
Siemes C et al (2006) C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 24(33):5216–5222
Touvier M et al (2013) Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol 177(1):3–13
Wang G et al (2015) A prospective follow-up study of the relationship between C-reactive protein and human cancer risk in the Chinese Kailuan Female Cohort. Cancer Epidemiol Biomarkers Prev 24(2):459–465
Zeleniuch-Jacquotte A et al (2008) Re: C-reactive protein and risk of breast cancer. J Natl Cancer Inst 100(6):443–444
Zhang SM et al (2007) C-reactive protein and risk of breast cancer. J Natl Cancer Inst 99(11):890–894
Wang J et al (2015) Plasma C-reactive protein and risk of breast cancer in two prospective studies and a meta-analysis. Cancer Epidemiol Biomarkers Prev 24(8):1199–1206
Nelson SH et al (2017) The Association of the C-Reactive Protein inflammatory biomarker with breast cancer incidence and mortality in the women's health initiative. Cancer Epidemiol Biomarkers Prev 26(7):1100–1106
Trichopoulos D et al (2006) Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 15(2):381–384
Frydenberg H et al (2016) Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival. Breast Cancer Res Treat 155(2):345–354
Heikkila K et al (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20(1):15–26
Allin KH, Bojesen SE, Nordestgaard BG (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27(13):2217–2224
Van Hemelrijck M et al (2011) Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev 20(3):428–437
American Diabetes A (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62–S69
Joshu CE et al (2012) Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) Study, 1990–2006. Int J Cancer 131(7):1667–1677
Giovannucci E et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33(7):1674–1685
Osei K et al (2003) Is glycosylated hemoglobin A1c a surrogate for metabolic syndrome in nondiabetic, first-degree relatives of African-American patients with type 2 diabetes? J Clin Endocrinol Metab 88(10):4596–4601
de Beer JC, Liebenberg L (2014) Does cancer risk increase with HbA1c, independent of diabetes? Br J Cancer 110(9):2361–2368
Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121(4):856–862
Liao S et al (2011) Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev 12(4):1061–1065
Boyle P et al (2012) Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 107(9):1608–1617
Bruning PF et al (1992) Insulin resistance and breast-cancer risk. Int J Cancer 52(4):511–516
Del Giudice ME et al (1998) Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47(2):111–120
Jernstrom H, Barrett-Connor E (1999) Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J Womens Health Gend Based Med 8(10):1265–1272
Manjer J et al (2001) Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmo Preventive Project. Eur J Cancer Prev 10(1):33–42
Yang G et al (2001) Population-based, case-control study of blood C-peptide level and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10(11):1207–1211
Kaaks R et al (2002) Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 13(4):307–316
Mink PJ et al (2002) Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 156(4):349–352
Muti P et al (2002) Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11(11):1361–1368
Keinan-Boker L et al (2003) Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 106(1):90–95
Lawlor DA, Smith GD, Ebrahim S (2004) Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control 15(3):267–275
Malin A et al (2004) Evaluation of the synergistic effect of insulin resistance and insulin-like growth factors on the risk of breast carcinoma. Cancer 100(4):694–700
Schairer C et al (2004) Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 108(5):773–779
Jee SH et al (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293(2):194–202
Lin J et al (2006) A prospective study of hemoglobin A1c concentrations and risk of breast cancer in women. Cancer Res 66(5):2869–2875
Rapp K et al (2006) Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 49(5):945–952
Miao Jonasson J et al (2012) HbA1C and cancer risk in patients with type 2 diabetes–a nationwide population-based prospective cohort study in Sweden. PLoS ONE 7(6):e38784
Kim JY et al (2018) Glycated hemoglobin and cancer risk in Korean adults: results from Korean Genome and Epidemiology Study. Clin Nutr Res 7(3):170–177
Bryant H et al (2006) Population-based cohort development in Alberta, Canada: a feasibility study. Chronic Dis Can 27(2):51–59
Robson PJ et al (2016) Design, methods and demographics from phase I of Alberta's Tomorrow Project cohort: a prospective cohort profile. CMAJ Open 4(3):E515–E527
Ye M et al (1098l) Cohort profile: Alberta's Tomorrow Project. Int J Epidemiol 46(4):1097–1098l
Borugian MJ et al (2010) The Canadian Partnership for Tomorrow Project: building a pan-Canadian research platform for disease prevention. CMAJ 182(11):1197–1201
Dummer TJB et al (2018) The Canadian Partnership for Tomorrow Project: a pan-Canadian platform for research on chronic disease prevention. CMAJ 190(23):E710–E717
USA North American Association of Central Cancer Registries 2016 2016 May 1, 2017]; https://www.naaccr.org/certified-in-2010-canadian-registries-list-and-map/
The 2017 Report on Cancer Statistics in Alberta. 2017, Alberta Health Services: CancerControl AB, Surveillance & Reporting: Edmonton, AB.
American Diabetes Association (2013) Standards of medical care in diabetes–2013. Diab Care 36(Suppl 1):S11–66
Guo L et al (2015) C-reactive protein and risk of breast cancer: a systematic review and meta-analysis. Sci Rep 5:10508
Gunter MJ et al (2015) Circulating adipokines and inflammatory markers and postmenopausal breast cancer risk. J Natl Cancer Inst 107(9):169
Bodmer M et al (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33(6):1304–1308
Cust AE et al (2009) The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat 113(3):567–576
Hope C et al (2016) Relationship between HbA1c and cancer in people with or without diabetes: a systematic review. Diabet Med 33(8):1013–1025
Parekh N et al (2013) Metabolic dysregulation of the insulin-glucose axis and risk of obesity-related cancers in the Framingham heart study-offspring cohort (1971–2008). Cancer Epidemiol Biomarkers Prev 22(10):1825–1836
Travier N et al (2007) Association between glycosylated hemoglobin and cancer risk: a New Zealand linkage study. Ann Oncol 18(8):1414–1419
Onitilo AA et al (2014) Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev 23(2):134–140
Goto A et al (2016) High hemoglobin A1c levels within the non-diabetic range are associated with the risk of all cancers. Int J Cancer 138(7):1741–1753
Suzuki Y et al (2017) BMI change and abdominal circumference are risk factors for breast cancer, even in Asian women. Breast Cancer Res Treat 166(3):919–925
Erickson K et al (2011) Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol 29(1):54–60
Gallagher D et al (1996) How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 143(3):228–239
Beeson WL et al (2010) Comparison of body composition by bioelectrical impedance analysis and dual-energy X-ray absorptiometry in Hispanic diabetics. Int J Body Compos Res 8(2):45–50
Libby P et al (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54(23):2129–2138
Pearson TA et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107(3):499–511
Meier-Ewert HK et al (2001) Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 47(3):426–430
Ockene IS et al (2001) Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47(3):444–450
Bunn HF, Gabbay KH, Gallop PM (1978) The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 200(4337):21–27
Acknowledgments
We would like to acknowledge the advice and contributions of Megan Farris, Joy Pader, and Yibing Ruan on this paper. Cancer registry data were obtained through linkage with Cancer Surveillance & Reporting, Cancer Research and Analytics, CancerControl Alberta. Tiffany Haig received graduate student funding support from the Canadian Institute of Health Research (CIHR). Darren Brenner was supported by a Canadian Cancer Society Capacity Development Award in Cancer Prevention (Grant No. 703917). The views expressed herein represent the views of the author(s) and not of Alberta’s Tomorrow Project or any of its funders. Alberta’s Tomorrow Project is only possible due to the commitment of its research participants, its staff and its funders: Alberta Health and the Alberta Cancer Prevention Legacy Fund, Alberta Cancer Foundation, Canadian Partnership Against Cancer and substantial in kind funding from Alberta Health Services.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Price, T.R., Friedenreich, C.M., Robson, P.J. et al. High-sensitivity C-reactive protein, hemoglobin A1c and breast cancer risk: a nested case–control study from Alberta’s Tomorrow Project cohort. Cancer Causes Control 31, 1057–1068 (2020). https://doi.org/10.1007/s10552-020-01329-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-020-01329-6